Key Points
-
Interested in Tonix Pharmaceuticals Holding Corp.? Here are five stocks we like better.
-
TONMYA sales are accelerating: Net sales rose from $3.7 million in the first quarter of 2026 to $11 million in the second quarter. Tonix has expanded its sales force and secured coverage agreements expected to reach about 46% of Americans by January 2027.
-
Lyme disease prevention trial is approaching: Tonix plans to begin a Phase II study of TNX-4800 early next year, enrolling about 3,300 participants across two Lyme seasons to evaluate the long-acting antibody’s ability to prevent infection.
-
Tonix maintains a funded development pipeline: The company is advancing TNX-1500 for kidney-transplant rejection and autoimmune applications, while reporting $176 million in cash, no debt and a cash runway into the second quarter of 2027.
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman told attendees at the Cantor Healthcare Conference that the company’s near-term focus is the commercial launch of TONMYA, its FDA-approved treatment for fibromyalgia in adults, while it advances development programs in Lyme disease prevention and transplant rejection.
Lederman described Tonix as a fully integrated biotechnology company that took TONMYA from development through FDA approval and launch. He said the company also has several Phase II or Phase II-ready programs, including TNX-4800, a long-acting monoclonal antibody intended to prevent Lyme disease, and TNX-1500, an anti-CD40 ligand antibody program for transplant rejection and autoimmune conditions.
TONMYA launch and payer access
→ 3 Lesser-Known Quantum Plays the Market May Be Overlooking Right Now
-
Is Tonix Pharmaceuticals the Next Biotech Breakout?
Lederman said TONMYA generated $3.7 million in net sales during the first quarter of 2026 and $11 million in the second quarter, representing a threefold sequential increase. The company has expanded its field force to 150 representatives from 100, he said.
Tonix has secured contracts with two of the three major pharmacy benefit manager group purchasing organizations on the commercial side as well as one of the three major managed Medicare organizations. He said the managed Medicare contract is expected to take effect in January 2027, when the company expects to have approximately 46% of Americans covered
→ Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
Lederman said broader access could be a potential driver of an inflection point in sales, though he said he could not predict when that would occur. He noted that commercial coverage takes time to filter through sub-plans and that regular Medicare coverage is not expected until Oct. 1, 2027. Tonix estimates Medicare could represent about 30% of its market, he said.
